Drug Trial Radar · NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Nov 11, 2024
Primary completion
Nov 2032
Study completion Nov 2032
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Northwell Health; Immunocore Ltd
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Conditions
- Uveal Melanoma
Interventions
TebentafuspDrug
Tebentafusp will be administered weekly i.v.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-Free survival (RFS)Time frame: 8.1 years from first patient in
Locations
15 sites in 9 countries. Site status is shown where the registry gives one.
Northwell Health -Center for Advanced Medicine
Lake Success, New York · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
Institut Curie - Hôpital de Paris
Paris, France · Recruiting
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany · Recruiting
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center
Hamburg, Germany · Recruiting
Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik
Heidelberg, Germany · Recruiting
Leiden University Medical Centre
Leiden, Netherlands · Recruiting
Erasmus MC
Rotterdam, Netherlands · Recruiting
Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland · Recruiting
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
L'Hospitalet de Llobregat, Spain · Recruiting
Hospital Clinico Universitario De Valladolid
Valladolid, Spain · Recruiting
Sahlgrenska Universitetssjukhuset
Gothenburg, Sweden · Recruiting
The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - Liverpool
Liverpool, United Kingdom · Recruiting
East and North Hertfordshire NHS Trust - Mount Vernon Hospital
Northwood, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.